ArticleAnnals of clinical and translational neurology2026
Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveIdentifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional
methodsTwenty-four PSP patients and 11 age- and sex-matched control subjects underwent Cerebrospinal fluid (CSF) and plasma assays of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (t-tau) using SIMOA. Ratios (NfL/t-tau, GFAP/t-tau, GFAP/NfL) were calculated. Tau burden was quantified using PI-2620 distribution volume ratio (DVR). Group comparisons and associations with tau-PET, MRI, and cognition were tested using Wilcoxon tests, ROC analyses, and age- and sex-adjusted linear models.
resultsPSP patients showed elevated NfL, GFAP levels, and higher NfL/t-tau and GFAP/t-tau ratios in CSF and plasma. CSF NfL/t-tau best discriminated PSP from control subjects (AUC = 0.99, 95% CI [0.97-1.00]; optimal cut-off: > 10), followed by CSF GFAP/t-tau (AUC = 0.89, 95% CI [0.76-1.00]; > 104) and plasma NfL/t-tau (AUC = 0.80, 95% CI [0.63-0.96]; 5.1). Plasma NfL/t-tau correlated with tau-PET DVR in the putamen (β = 0.63; 95% CI [0.15-1.11]; p < 0.01) and pallidum (β = 0.54, 95% CI [0.07-1.02]; p < 0.01) and predicted disease severity (β = 0.61, 95% CI [0.19, 1.04]; p = 0.007) and processing speed (β = 0.66, 95% CI [0.22, 1.10]; p = 0.006), explaining 35% and 33% of variance, respectively. Frontal MRI volume modestly improved prediction of processing speed (ΔR
interpretationPlasma NfL/t-tau correlates with regional tau, disease severity, and cognition. Fluid biomarkers, complemented by PET and MRI, may support multimodal PSP diagnosis, monitoring, and trial stratification.
trial registrationAustralian New Zealand Clinical Trials Registry: ACTRN12620001254987.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.